Skip to content
← Full study record

NCT00574288 · MORE INFO

Limitations, agreements, and source contact

Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma · Source last updated 2018-04-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialDisclosure@its.jnj.com
organization
Janssen Research & Development, LLC
title
Senior Director
Complete source fields
certain Agreement
other Details
If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialDisclosure@its.jnj.com
organization
Janssen Research & Development, LLC
title
Senior Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice